A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
Study Number: SCRI ZL-1310-003
Study Summary:
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Status: Open
Peoria, Bloomington, Galesburg, Pekin, Peru, Ottawa, Washington
Study Coordinator(s)
- Angie, 309-243-3613, aearles@illinoiscancercare.com
- Hannah, 309-243-3628 hknight@illinoiscancercare.com
- Navigator Heather, 309-243-3661 hthulean@illinoiscancercare.com
